Gapping down
In reaction to disappointing earnings/guidance:
- TEAM -5.8%, PRO -4.9%, MOH -4.8%, EXPE -4.6%, SHAK -4.3%, AROC -3.6%, EGHT -3.5%, GILD -3.4%, ZEN -3.4%, XLNX -3.3%, SYK -3%, XPO -2.7%, MERC -2.7%, CVX -2.7%, FORM -2.6%, NVST -2.6%, RDFN -2.3%, SGEN -2.2%, CASA -2.1%, TWOU -2%, NATI -1.3%, XOM -1%, PBR -0.9%, MTD -0.8%, FTAI -0.7%, BTI -0.7%, CBRE -0.7%, DECK -0.6%
Other news:
- WRTC -7% (names new CEO)
- RDHL -2% (FDA clearance of IND application for a pivotal Phase 3 study to evaluate the efficacy and safety of RHB-204 in adults with pulmonary nontuberculous mycobacteria disease)
- GOGO -0.9% (provides update on pandemic, includes job cuts)
- HZNP -0.9% (announces positive topline data from two clinical trials that add to the growing body of evidence supporting the efficacy and safety of TEPEZZA for the treatment of Thyroid Eye Disease
Analyst comments:
- DBX -1.1% (downgraded to Neutral from Buy at BofA Securities)
- K -0.5% (downgraded to Neutral from Buy at Goldman)